Format

Send to

Choose Destination
Nat Rev Microbiol. 2009 May;7(5):393-400. doi: 10.1038/nrmicro2129.

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Author information

1
Biodefense Research Section, Bethesda, Maryland 20892, USA. nsullivan@nih.gov

Erratum in

  • Nat Rev Microbiol. 2009 Sep;7(9):684.

Abstract

Ebola virus infection is a highly lethal disease for which there are no effective therapeutic or preventive treatments. Several vaccines have provided immune protection in laboratory animals, but because outbreaks occur unpredictably and sporadically, vaccine efficacy cannot be proven in human trials, which is required for traditional regulatory approval. The Food and Drug Administration has introduced the 'animal rule', to allow laboratory animal data to be used to show efficacy when human trials are not logistically feasible. In this Review, we describe immune correlates of vaccine protection against Ebola virus in animals. This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule.

PMID:
19369954
DOI:
10.1038/nrmicro2129
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center